Cepheid announced this week that it is shipping new versions of its GeneXpert system.
The company said the new system offers increased color capability, detection of up to 60 targets in one cartridge, and software for integrating laboratory information systems.
Clarient announced this week plans to commercialize a breast cancer test applicable for all stages of operable breast cancer, including lymph node-positive patients.
According to Clarient, its test, called Insight Dx Breast Cancer Profile, is the first molecular test of its kind.
Clarient holds an exclusive licensing agreement with Prediction Sciences to sell the test.
The Insight Dx Breast Cancer Profile comprises “a series of molecular assays that, when combined using Prediction Sciences' proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy,” Clarient said in a statement.
“The profile could allow patients to avoid the toxic effects of unnecessary chemotherapy, thereby reducing the overall cost of care,” the company stated.
The Insight Dx Breast Cancer Profile will enter a competitive breast cancer recurrence testing market valued at between $300 million and $400 million annually in the US. Currently several companies, including Genomic Health, Agendia, and Exagen, market breast cancer recurrence tests.